KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash & Current Investments: 2018-2024

Historic Cash & Current Investments for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Dec 2024 value amounting to $358.5 million.

  • Aurinia Pharmaceuticals' Cash & Current Investments rose 0.88% to $351.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 0.84%. This contributed to the annual value of $358.5 million for FY2024, which is 2.28% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Cash & Current Investments stood at $358.5 million for FY2024, which was up 2.28% from $350.5 million recorded in FY2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Cash & Current Investments peaked at $466.1 million during FY2021, and registered a low of $350.5 million during FY2023.
  • Its 3-year average for Cash & Current Investments is $366.1 million, with a median of $358.5 million in 2024.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 30.16% in 2020, then fell by 16.45% in 2022.
  • Yearly analysis of 5 years shows Aurinia Pharmaceuticals' Cash & Current Investments stood at $398.3 million in 2020, then rose by 17.01% to $466.1 million in 2021, then dropped by 16.45% to $389.4 million in 2022, then dropped by 9.99% to $350.5 million in 2023, then increased by 2.28% to $358.5 million in 2024.